| Literature DB >> 33077175 |
Maria Anita Costa Spindola1, Dirceu Solé2, Marcelo Vivolo Aun3, Liana Maria Tôrres de Araújo Azi4, Luiz Antonio Guerra Bernd5, Daniela Bianchi Garcia6, Albertina Varandas Capelo7, Débora de Oliveira Cumino8, Alex Eustáquio Lacerda2, Luciana Cavalcanti Lima9, Edelton Flávio Morato10, Rogean Rodrigues Nunes11, Norma de Paula Motta Rubini12, Jane da Silva1, Maria Ângela Tardelli13, Alexandra Sayuri Watanabe14, Erick Freitas Curi15, Flávio Sano16.
Abstract
Experts from the Brazilian Association of Allergy and Immunology (ASBAI) and the Brazilian Society of Anesthesiology (SBA) interested in the issue of perioperative anaphylaxis, and aiming to strengthen the collaboration between the two societies, combined efforts to study the topic and to prepare a joint document to guide specialists in both areas. The purpose of the present series of two articles was to report the most recent evidence based on the collaborative assessment between both societies. This first article will consider the updated definitions, treatment and guidelines after a perioperative crisis. The following article will discuss the major etiologic agents, how to proceed with the investigation, and the appropriate tests.Entities:
Keywords: Alergia e imunologia; Allergy and immunology; Anafilaxia; Anaphylaxis; Hipersensibilidade; Hypersensitivity; Perioperative period; Período perioperatório
Mesh:
Year: 2020 PMID: 33077175 PMCID: PMC9373446 DOI: 10.1016/j.bjan.2020.06.004
Source DB: PubMed Journal: Braz J Anesthesiol ISSN: 0104-0014
Classification of severity and clinical signs of anaphylaxis.14, 15, 16
| Severity | Clinical signs |
|---|---|
| Grade I | Generalized cutaneous and mucosal signs: erythema, urticaria, with or without edema. |
| Grade II | Moderate multivisceral condition with cutaneomucosal signs, arterial hypotension (systolic drop > 30%), tachycardia (>30%), bronchial hyperreactivity (coughing, difficulty breathing). |
| Grade III | Severe multivisceral disease, life threatening, requiring specific therapy: cardiovascular collapse, tachycardia or bradycardia, arrhythmias, bronchospasm. Skin signs are absent or appear after blood pressure correction. |
| Grade IV | Cardiorespiratory arrest. |
Diagnosis of perioperative anaphylaxis.
| Factors that can contribute to delayed diagnosis | Anesthetized patient does not report malaise, dizziness or itching. |
AW, airway; IV, intravenous.
Differential diagnosis of intraoperative hypersensitivity. Adapted from 15, 26, 27
| Airways | Circulation | Cutaneous |
|---|---|---|
| Upper | Hypovolemia | Skin-restricted signs |
ACE, angiotensin-converting enzyme; COX, cyclooxygenase.
Possible triggers of hypersensitivity reaction in the intraoperative period, according to anesthesia timeline. Adapted from 29, 30, 31.
| Anesthetic induction | Up to 30 minutes of induction | After 30 minutes of induction | End of surgery |
|---|---|---|---|
| Induction agents – neuromuscular blockers | Latex | Blood products | Non-steroidal anti-inflammatory drugs |
| Colloids | Bone cement with antibiotic | Opioids | |
| Antibiotics | Contrasts | Release of tourniquet | Anesthetic reversal agents |
| Dyes (blue) | |||
| Impregnated intravenous catheters | Chlorhexidine | ||
| Exposure routes other than intravenous |
Management according to severity.7, 15, 26
| Epinephrine must be administered IM – before solution preparation, monitoring or venous access is obtained. | |||
|---|---|---|---|
| Grade I | Grade II | Grade III | Grade IV |
| Assess progress | Epinephrine | Epinephrine | Epinephrine |
| Crystalloid (not colloid) IV fluid therapy 20 mg.kg−1 (bolus). Repeat. | |||
| • IM Epinephrine: vastus lateralis muscle/middle third. | |||
IM, intramuscular; OTI, orotracheal intubation; SBP, systolic blood pressure; EtCO2, end-tidal CO2.
Immediate treatment of anaphylaxis. Adapted from 7, 26, 30, 39.
| Early diagnosis | Epinephrine adequate dose | Adequate volume and dose |
|---|---|---|
| Alert signs | Immediate general measures | Consider |
| • Hypotension | • Eliminate suspected agent | • Pharmacological actions of general/local anesthetics |
Absence of cutaneous signs does not rule out anaphylaxis.
Epinephrine dilution methods.
| Infusion | |
|---|---|
| The only presentation available in Brazil for adrenaline contains 1,000 mg.mL−1 | Start after 3 boluses of intravenous adrenaline. Peripheral vein can be used |
| - Dilute 1 ml of epinephrine standard presentation (1 mg.mL−1) in 9 ml of diluent (distilled water or 0.9% saline) = >100 mcg.mL−1 concentration | - Dilute 3 ml of epinephrine standard presentation (1 mg.mL−1) in 50 ml of 0.9% saline solution = >60 mcg.mL−1 concentration |
| - Dilute 1 ml of the solution with a concentration of 100 mcg.mL−1 in 9 ml of diluent (distilled water or 0.9% saline) = >final concentration of 10 mcg.mL−1 | |
| For Grade II: | Start with 3 mL.h−1 = 3 mcg.min−1 |
| 10 to 20 mcg (1 to 2 ml) | Titrate up to 40 mL.h−1 = 40 mcg.min−1 |
| For Grade III: | Infusion rate = 0.05–0.5 mcg.kg.min−1 |
| 100 to 200 mcg (10 to 20 ml) |
Refractory anaphylaxis management.7, 26, 46, 47
| Initially question whether all antigens have been removed (Chlorhexidine? Latex? Synthetic colloids?) |
| Tryptase sampling |
| • Norepinephrine |
| Dose = 0.05–0.1 mcg.kg.min−1 |
| • Glucagon (for patients using beta-blockers) |
| Dose = 1–2 mg ou 5–15 mcg.min−1. Repeat after 5 minutes. |
| • Vasopressin |
| |
| Alternatively: infusion of 0.2–0.4 UI.min−1 or 2 UI.h−1. |
| • Inhaled Salbutamol |
| • Consider volatile agents |
| • IV Bronchodilators |
| Ketamine |
| Salbutamol |
Note: Sugammadex has no proven role in the treatment of suspected anaphylaxis reactions.
Suggested management for suspected anaphylaxis and perioperative allergy in children.7, 26
| Epinephrine | IV Fluids | |
|---|---|---|
| - Consider arterial line |
Note: Titrate epinephrine until response; if large doses are necessary, use IV infusion. Epinephrine dilution, 1: 10,000 for every 10 kg.
Follow-up after the anaphylactic reaction.7, 30, 39, 82, 83
| Grade I | Grade II | Grade III | Grade IV |
|---|---|---|---|
| Medical discharge after clinical resolution | Monitoring at PACU | Resuscitation/monitoring in PACU | Resuscitation/ICU monitoring for 24 h |
PACU, post-anesthetic recovery room.
Procedures to be follow at hospital discharge of patient.7, 15, 26, 30, 39
| ▪ Make sure the complication was recorded on patient medical chart |
| ▪ Provide the patient with a written report by the anesthesiologist with a complete list of drugs to avoid until further evaluation/Attach a copy of the report to the patient medical chart |
| ▪ Consultation with allergist within 4–6 weeks after hospital discharge |